Augmented emicizumab-driven coagulation potential in hemophilia A state by <i>in vitro</i> and <i>in vivo</i> supplementation of combined factors IX and X.

ABSTRACT:

Background

Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs. Recent studies have demonstrated that either factor (F)IX or FX supplementation can improve coagulation potential of emicizumab-treated persons with HA and inhibitors.

Objectives

This study assessed the effect of combined supplementation with FIX and FX on the coagulation potential in emicizumab-treated HA state.

Methods

FVIII-deficient plasmas were spiked with emicizumab (50 μg/mL), FX (100 IU/dL), and various FIX levels (100-1600 IU/dL). Plasmas from emicizumab-treated persons with HA and inhibitors were also added with FIX/FX (100 IU/dL each). Coagulation potential was assessed by maximum coagulation velocity (Ad|min

SUBMITTER: Osuna M 

PROVIDER: S-EPMC12856453 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature